ANTIMICROBIAL ACTIVITY AND CLINICAL VALUE OF BMY-28100 IN URINARY TRACT INFECTION

• Published in: CHEMOTHERAPY Vol. 37; no. Supplement3; pp. 545 - 558
• Main Authors: YAMAHA, MASAYOSHI, HAYASHI, HIDEJI, SHINODA, IKUO, SAITOH, AKIHIRO, TAKEUCHI, TOSHIMI, KANEMATSU, MINORU, BAN, YOSHIHITO, KAWADA, YUKIMICHI, SAKAI, SHUNSUKE, KATOH, HARU, ISHIHARA, SATOSHI, FUJIMOTO, YOSHINORI, HARADA, YOSHIMASA
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1989
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.37.Supplement3_545

We studied the antimicrobial activity against urinary isolates and the clinical value of BMY-28100, a new oral cephem. The in vitro activity of BMY-28100 against Gram-negative bacteria was nearly the same as that of cefaclor (CCL), but it was more active against Gram-positive bacteria than CCL. BMY-28100 was orally administered to patients with urinary tract infection (UTI) for 3-5 days, and the clinical efficacy of BMY-28100 was evaluated using the criteria proposed by the Japanese UTI Committee. The clinical efficacy rate in 9 cases of acute uncomplicated cystitis (500mg a day) was as high as 100%, and in 25 cases of chronic complicated UTI (750 mg a day) it was 64%. Adverse reactions were observed in 5 cases (diarrhea and loose stool in 3, rash in 1 and elevation of GPT in 1), but they were mild in degree. On the basis of our results, we consider BMY-28100 to be a useful drug for acute uncomplicated cystitis and complicated UTI, especially with polymicrobial infection.